119 related articles for article (PubMed ID: 37934043)
1. Longitudinal change in CDC42 in psoriasis: correlation with disease activity and treatment response.
Xu B; Fan L; Liu Q; Guo B; Yang T; Zhang Y
Biomark Med; 2023 Aug; 17(16):657-666. PubMed ID: 37934043
[TBL] [Abstract][Full Text] [Related]
2. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
[TBL] [Abstract][Full Text] [Related]
3. Dual specificity phosphatase 22 relates to skin lesion degree and biologics history, while its longitudinal elevation during treatment reflects better outcome in psoriasis patients.
E C; Fang Y; Wu S; Meng Z; Qin G; Yang J
J Clin Lab Anal; 2022 Feb; 36(2):e24199. PubMed ID: 34973040
[TBL] [Abstract][Full Text] [Related]
4. Measurement of circulating miRNA-125a exhibits good value in the management of etanercept-treated psoriatic patients.
Pei D; Cao J; Qin G; Wang X
J Dermatol; 2020 Feb; 47(2):140-146. PubMed ID: 31820498
[TBL] [Abstract][Full Text] [Related]
5. Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients.
Jin W; Zhang S; Duan Y
Dermatology; 2019; 235(1):55-64. PubMed ID: 30408786
[TBL] [Abstract][Full Text] [Related]
6. Plasma miR-126 expression correlates with risk and severity of psoriasis and its high level at baseline predicts worse response to Tripterygium wilfordii Hook F in combination with acitretin.
Duan Y; Zou J; Mao J; Guo D; Wu M; Xu N; Zhou J; Zhang Y; Guo W; Jin W
Biomed Pharmacother; 2019 Jul; 115():108761. PubMed ID: 31100542
[TBL] [Abstract][Full Text] [Related]
7. Blood MALT1 expression could help predict treatment outcomes in psoriasis patients, especially in those receiving biologics.
Liu Q; Zhang Y; Xu B; Jin X; Yang T; Fan L
Immun Inflamm Dis; 2024 Apr; 12(4):e1235. PubMed ID: 38578002
[TBL] [Abstract][Full Text] [Related]
8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
9. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
10. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study.
Boehncke S; Salgo R; Garbaraviciene J; Beschmann H; Hardt K; Diehl S; Fichtlscherer S; Thaçi D; Boehncke WH
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1187-93. PubMed ID: 21241371
[TBL] [Abstract][Full Text] [Related]
11. Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study.
Montaudié H; Albert-Sabonnadière C; Acquacalda E; Fontas E; Danré A; Roux C; Ortonne JP; Lacour JP; Euller-Ziegler L; Passeron T
J Eur Acad Dermatol Venereol; 2014 Sep; 28(9):1186-91. PubMed ID: 23981008
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-146a and microRNA-146b deficiency correlates with exacerbated disease activity, and their longitude increment relates to etanercept response in psoriasis patients.
Shen H; Wang D; Zhan M; Ding H; Zhao H
J Clin Lab Anal; 2022 Feb; 36(2):e24198. PubMed ID: 34952998
[TBL] [Abstract][Full Text] [Related]
13. Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors.
Qian M; Song NJ
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(13):4299-4309. PubMed ID: 30024620
[TBL] [Abstract][Full Text] [Related]
14. Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept.
Yang A; Xin X; Yang W; Li M; Yang W; Li L; Liu X
Ann Dermatol Venereol; 2019 May; 146(5):363-371. PubMed ID: 31047699
[TBL] [Abstract][Full Text] [Related]
15. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
17. Effect of CoQ10 Administration to Psoriatic Iraqi Patients on Biological Therapy Upon Severity Index (PASI) and Quality of Life Index (DLQI) Before and After Therapy.
Al-Oudah GA; Sahib AS; Al-Hattab MK; Al-Ameedee AA
J Popul Ther Clin Pharmacol; 2022; 29(2):e52-e60. PubMed ID: 35848197
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A
Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Psoriasis Area and Severity Index Thresholds as Proxies for Systemic Inflammation on an Individual Patient Level.
Hoffmann JHO; Enk AH
Dermatology; 2022; 238(4):609-614. PubMed ID: 34852349
[TBL] [Abstract][Full Text] [Related]
20. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.
Bruins FM; Bronckers IMGJ; Groenewoud HMM; van de Kerkhof PCM; de Jong EMGJ; Seyger MMB
JAMA Dermatol; 2020 Jan; 156(1):72-78. PubMed ID: 31774449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]